The Changing Landscape in Triple-Negative Breast Cancer: Managed Care Strategies for Formulary Management
English
Recorded Courses
hosted by Pharmacy Times Continuing Education (PTCE)
hosted by Pharmacy Times Continuing Education (PTCE)
attend it anywhere online
category
Medicine, Pharmacy
Oncology
price
Free
Description:,Triple-negative breast cancer (TNBC) tumors lack expression of estrogen, progesterone, and human epidermal growth factor 2 (HER2) receptors and are therefore not sensitive to endocrine therapy or HER2-directed treatment. Targeted treatments, including existing immunotherapy agents and a novel antibody-drug conjugate (ADC) have improved progression-free survival in metastatic TNBC. As additional therapies are approved for metastatic TNBC and treatment algorithms and recommendations evolve, pharmacists involved in managed care must ensure clinical treatment pathways are reviewed and amended and patients with TNBC have access to and are receiving emerging therapies. This activity will focus on systemic management tools to both improve patient outcomes and reduce healthcare resource utilization in TNBC. Strategies outlined will include the implementation and maintenance of oncology clinical pathways as well as approaches to ensure adherence to clinical pathways and delivery of cost-effective, clinically appropriate care for patients with metastatic TNBC.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Examine the impact of recent immune checkpoint inhibitor and antibody-drug conjugate clinical trials on the current landscape and treatment guidelines for metastatic triple-negative breast cancer (mTNBC).,• Investigate utilization management strategies to optimize the accessibility of therapies for the treatment of mTNBC.,• Identify the roles of managed care pharmacists in the implementation and optimization of formulary changes for the treatment of mTNBC.